文献速递骨质疏松与代谢性骨病

澳大利亚骨质疏松卫生经济学模型风险引擎的开发与验证

Development and validation of the risk engine for an Australian Health Economics Model of Osteoporosis.
PubMed 文献 · Osteoporos Int · 2021-04-15

本研究旨在记录并验证澳大利亚骨质疏松卫生经济学模型(AusHEMO)的风险引擎。AusHEMO是一种状态转换微观模拟模型,骨折风险使用Dubbo骨质疏松流行病学研究的发生率模拟。模型在表面效度、内部效度和交叉效度方面均表现良好,Lin一致性系数分别为0.99、1和0.94。

要点

  • AusHEMO风险引擎的开发遵循骨质疏松疾病建模的最佳实践。
  • 模型在骨折发生率、澳大利亚预期寿命和残余终生骨折风险验证中显示良好效度。
  • AusHEMO可用于预测长期骨折相关结局和卫生经济学评价。

核心结论

  • AusHEMO风险引擎的开发遵循骨质疏松疾病建模最佳实践,模型具有良好表面效度、内部效度和交叉效度。
  • AusHEMO可自信用于预测长期骨折相关结局及包含成本数据的卫生经济学评价。

研究设计与样本

  • AusHEMO是一种状态转换微观模拟模型,骨折风险使用Dubbo骨质疏松流行病学研究的发生率模拟。
  • 本研究对AusHEMO进行表面效度、内部效度和交叉效度验证,并报告拟合优度分析、Lin一致性系数及平均绝对差与95%一致性限。

主要发现

  • AusHEMO在模型结构、证据、问题表述和结果方面显示良好表面效度。
  • 拟合优度检验证明模型具有良好内部效度和交叉效度。
  • 验证骨折发生率、澳大利亚预期寿命和残余终生骨折风险的Lin一致性系数分别为0.99、1和0.94。

关键数值与推荐

  • 验证骨折发生率的Lin一致性系数为0.99。
  • 验证澳大利亚预期寿命的Lin一致性系数为1。
  • 验证残余终生骨折风险的Lin一致性系数为0.94。

临床怎么用

  • 澳大利亚卫生政策制定者可使用AusHEMO选择具有成本效益的骨质疏松干预措施,如药物和公共卫生干预。
  • AusHEMO可辅助澳大利亚医疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The Australian Health Economics Model of Osteoporosis (AusHEMO) has shown good face, internal and cross validities, and can be used to assist healthcare decision-making in Australia. PURPOSE: This study aimed to document and validate the risk engine of the Australian Health Economics Model of Osteoporosis (AusHEMO). METHODS: AusHEMO is a state-transition microsimulation model. The fracture risks were simulated using fracture incidence rates from the Dubbo Osteoporosis Epidemiology Study. The AusHEMO was validated regarding its face, internal and cross validities. Goodness-of-fit analysis was conducted and Lin's coefficient of agreement and mean absolute difference with 95% limits of agreement were reported. RESULTS: The development of AusHEMO followed general and osteoporosis-specific health economics guidelines. AusHEMO showed good face validity regarding the model's structure, evidence, problem formulation and results. In addition, the model has been proven good internal and cross validities in goodness-of-fit test. Lin's coefficient was 0.99, 1 and 0.94 for validation against the fracture incidence rates, Australian life expectancies and residual lifetime fracture risks, respectively. CONCLUSIONS: In summary, the development of the risk engine of AusHEMO followed the best practice for osteoporosis disease modelling and the model has been shown to have good face, internal and cross validities. The AusHEMO can be confidently used to predict long-term fracture-related outcomes and health economic evaluations when costs data are included. Health policy-makers in Australia can use the AusHEMO to select which osteoporosis interventions such as medications and public health interventions represent good value for money.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Si L, Eisman JA, Winzenberg T, et al. Development and validation of the risk engine for an Australian Health Economics Model of Osteoporosis. Osteoporos Int. 2021. PMID: 33856500. doi:10.1007/s00198-021-05955-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。